Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality

European Journal of Haematology

Volumn 78, Issue 6, 2007, Pages 487-494

  Takatoku, Masaaki ^a   Uchiyama, Takashi ^b   Okamoto, Shinichiro ^c   Kanakura, Yuzuru ^d   Sawada, Kenichi ^e   Tomonaga, Masao ^f   Nakao, Shinji ^g   Nakahata, Tatsutoshi ^b   Harada, Mine ^h   Murate, Takashi ⁱ   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e AKITA UNIVERSITY   (Japan)

^f NAGASAKI UNIVERSITY   (Japan)

^g KANAZAWA UNIVERSITY   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ NAGOYA UNIVERSITY   (Japan)

Author keywords

Aplastic anemia; Deferoxamine; Iron chelation therapy; Myelodysplastic syndromes; Refractory anemias

Indexed keywords

DEFEROXAMINE; FERRITIN; LIVER ENZYME;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; APLASTIC ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HUMAN; IRON CHELATION; IRON OVERLOAD; JAPAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, APLASTIC; BLOOD TRANSFUSION; CAUSE OF DEATH; DEFEROXAMINE; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; JAPAN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES;

EID: 34248569916     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00842.x     Document Type: Article

References (29)

1. Japan Intractable Diseases Information Center. Available at: http://www.nanbyou.or.jp.
2. Gabutti V, Borgna-Pignatti C. Clinical manifestations and therapy of transfusional haemosiderosis. Bailliere's Clin Haematol 1994 7 : 919 40.
3. McLaren GD, Muir WA, Kellermeyer RW. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci 1983 19 : 205 66.
4. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. In : Hematology/American Society of Hematology Education Program Book. American Society of Hematology, 2001. Available at: http://www.asheducationbook.org/cgi/ content/full/2001/1/47.
5. Ehlers KH, Levin AR, Markenson AL, Marcus JR, Klein AA, Hilgartner MW, Engle MA. Longitudinal study of cardiac function in thalassemia major. Ann New York Acad Sci 1980 344 : 397 404.
6. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986 6 : 24 29.
7. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997 25 : 162 6.
8. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes in thalassaemia. Arch Dis Child 1988 63 : 58 62.
9. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest 2002 32 (s1 70 78.
10. Bullen JJ. The significance of iron in infection. Rev Infect Dis 1981 3 : 1127 38.
11. Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Comp Cancer Net 2006 4 : 58 77.
12. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003 120 : 187 200.
13. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002 7 : 1286 306.
14. Gattermann N, Porter J, Lopes LF, Seymour J. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am 2005 19 (s1 18 25.
15. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision-making. J Clin Oncol 2005 23 : 7594 603.
16. Wolfe L, Olivieri N, Sallan D. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985 312 : 1600 3.
17. Giardina PJ, Ehlers KH, Engle MA, Grady RW, Hilgartner MW. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study. Ann New York Acad Sci 1985 445 : 282 92.
18. Schafer AI, Cheron RG, Dluhy R. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981 304 : 319 24.
19. Lu J-P, Hayashi K. Selective iron deposition in pancreatic islet B cells of transfusional iron-overloaded autopsy cases. Pathol Int 1994 44 : 194 9.
20. Thalassaemia International Federation. Guidelines for the Clinical Management of Thalassaemia. Thalassaemia International Federation, 2002. Available at: http://www.thalassaemia.org.cy/Publications.htm.
21. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes-v.4. 2006. NCCN, 2006. Available at: http://www.nccn.org.
22. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000 355 : 2051 2.
23. Leitch HA, Goodman TA, Wong KK, Vickars LM, Galbraith PF, Leger CS. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. Blood 2006 108 : abstract 249.
24. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996 95 : 26 36.
25. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994 331 : 567 73.
26. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegaard J. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996 94 : 288 99.
27. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006 91 : 873 80.
28. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006 107 : 3455 62.
29. Porter J, Vichinsky E, Rose C, Piga A, Olivieri N, Gattermann N, Maertens J, Rabault B, Gathmann I, Alberti D. A phase II study with ICL670 (Exjade®), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload. Blood 2004 104 : abstract 3193.